Scarica l'app Stockscreener
0.0853
5.22%
-0.0047
Eyenovia Inc Borsa (EYEN) Ultime notizie
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
Eyenovia faces Nasdaq delisting over low stock price By Investing.com - Investing.com Australia
Eyenovia faces Nasdaq delisting over low stock price - Investing.com
Eyenovia’s $1.9M Offering to Boost Optejet Development - TipRanks
Form 424B5 EYENOVIA, INC. - StreetInsider.com
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia announces pricing of $1.9M registered direct offering - MSN
Eyenovia secures $1.9 million in direct offering By Investing.com - Investing.com Canada
Eyenovia secures $1.9 million in direct offering - Investing.com
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewswire
Eyenovia Announces $1.9M Direct Offering to Fund Optejet Development, Strategic Growth - StockTitan
These Numbers Show Just How Powerful Eyenovia Inc (NASDAQ: EYEN) Stock Is - Stocks Register
Eyenovia’s Direct Offering to Support Strategic Initiatives - TipRanks
Eyenovia secures $1.3 million in direct offering By Investing.com - Investing.com South Africa
Eyenovia (NASDAQ:EYEN) Enters Into First Amendment to Loan Agreement and Subscription Agreement - Defense World
Eyenovia defers loan payments, issues equity to lenders - Investing.com
Eyenovia defers loan payments, issues equity to lenders By Investing.com - Investing.com Canada
Eyenovia Slumps On Pricing Of Registered Direct Offering - Nasdaq
Eyenovia Restructures Finances and Leadership Team - TipRanks
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - The Manila Times
Eyenovia secures $1.3 million in direct offering - Investing.com
Eyenovia Raises $1.3M in Direct Offering at $0.1076 Per Share with Warrants | EYEN Stock News - StockTitan
Eyenovia taking additional actions to reduce personnel-related costs by over 70% - Yahoo Finance
Eyenovia secures debt payment deferral from Avenue Capital By Investing.com - Investing.com Nigeria
Eyenovia Continues to Evaluate Broad Range of Strategic Alternatives to Maximize Stakeholder Value - Marketscreener.com
Eyenovia secures debt payment deferral from Avenue Capital - Investing.com
Eyenovia Provides Update on Restructuring Efforts - The Manila Times
Eyenovia reports low cash reserves; in talks for debt restructuring By Investing.com - Investing.com South Africa
Eyenovia reports low cash reserves; in talks for debt restructuring - Investing.com
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - MSN
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
William Blair Reaffirms “Market Perform” Rating for Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management - Defense World
Eyenovia stock plummets following Phase III myopia trial failure - Clinical Trials Arena
Black Friday for Eyenovia as shares fall 70% - The Pharma Letter
Eyenovia stock downgraded to Neutral, price target set on challenges By Investing.com - Investing.com UK
Eyenovia halts myopia study after missing primary endpoint - Investing.com India
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study - Marketscreener.com
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints - MarketWatch
Eyenovia to end eye drug study, cut 50% of its workforce - Reuters
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - AOL
Eyenovia Shares Plumb New Depths After Study Failure - MarketWatch
Eyenovia Shares Plummet 70% After It Drops Lead Program - BioSpace
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):